Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Energy Select Sector SPDR Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Energy Select Sector SPDR Fund trades at $55.73. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | XLE | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $62.57 |
52-Week Low | $278.09 | $42.12 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XLE, the Energy Select Sector SPDR ETF, trades at $55.08, up 0.49% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF has gained 21% year-to-date as of July 2, 2026 (ETF Trends), benefiting from oil price volatility and geopolitical tensions. Recent news highlights sector strength, though oil price fluctuations and concentration in 21 holdings pose considerations.
Outlook remains supported by energy demand and disciplined capital expenditure, but risks include oil price sensitivity and political pressure. Analyst sentiment is mixed, with technical strength offsetting fundamental valuation gaps. The dividend yield and expense ratio advantages are positive, yet investors face volatility from crude market dynamics and election-related policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
